Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:06:47.982Z.
Calculation as of: 2026-10-06T14:06:47.982Z.
Quote observation: 2026-10-06T14:01:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 786381cf23009ce26769892c1927912581314c354aa2592277191dd3add0e379
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$31.23M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GridAI Technologies Corp. (GRDX) | $28.20M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $28.13M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.67M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $29.63M | N/A | 392.49% | 233.09% | 233.09% |
| MDxHealth S.A. (MDXH)vs › | $30.86M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.84M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.23M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.46M | N/A | 0.01% | 0.01% | 0.01% |
| BeyondSpring Inc. (BYSI)vs › | $31.46M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $31.52M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute